search icon
  • Print
  • ShareThis
  • Text Size
  • NIH Member Spotlight: Dr. F. Matthew Kuhlmann

    Instructor in Medicine, Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO

    Dr. Kuhlmann’s research focuses on predicting outcomes to enteric pathogens, namely E. coli, in order to develop improved vaccines. His clinical interests include infectious diseases, parasitology, and travel medicine.

    Dr. Kuhlmann’s NIH Supported Research

    Dr. Kuhlmann’s NIH-supported work addresses the need to improve candidate vaccines for enterotoxigenic E. coli (ETEC), one of the most common causes of severe bacterial diarrhea worldwide.

    • Vaccines targeting ETEC appear feasible based on protection observed in challenge models and the presumptive development of immunity to natural infection.

    • Traditional vaccine approaches have been unable accommodate the extensive diversity of ETEC pathogens, leading to a search for novel antigens involved in ETEC pathogenesis that complement traditional approaches.

    The main objective of Dr. Kulhmann’s research is to advance the development of novel antigens as key contributors to an effective ETEC vaccine. It will provide data to help drive the rational design of novel ETEC vaccines as well as rapid means to assess their efficacy.

    Impact on Patients and Public Health

    ETEC are the most common cause of bacterial diarrhea among children and travelers. The disease primarily afflicts children in the poorest regions of the world, contributing to excessive morbidity and mortality associated with diarrheal illness. Vaccines to prevent or curtail ETEC infections are urgently needed to improve the health of vulnerable and limited-resource populations.

| HIVMA | Contact Us

© Copyright IDSA 2018 Infectious Diseases Society of America

Full Site Mobile Site